3401 Princeton Pike, Lawrenceville, NJ 08648

UPDATED NOTIFICATION OF SUPPLY ALLOCATION: VIDAZA® (azacitidine)
October 1, 2021

This notice provides ***updated*** information for 340B covered entities that Celgene Corporation ("Celgene"), a subsidiary of Bristol Myers Squibb Company, markets VIDAZA® (azacitidine) (for subcutaneous or intravenous use) ("VIDAZA"):

Product	Description	NDC NUMBER
VIDAZA® (azacitidine)	Lyophilized powder in 100 mg single-dose vial	59572-102-01

VIDAZA is a nucleoside metabolic inhibitor indicated for the treatment of patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).

As update to November 18, 2020 Notice of Supply Allocation, effective October 1, 2021 Bristol Myers Squibb has resolved the global supply constraints for VIDAZA. At current time all limitations on purchasing of VIDAZA in the United States have been removed for 340B and non-340B entities. Bristol Myers Squibb will continue to monitor supply and demand trends for VIDAZA to proactively add supply in effort to minimize disruption to patient care.

Bristol Myers Squibb takes its obligations under the 340B program seriously and regret any inconvenience the temporary supply constraint may have caused. If you have any questions regarding this program, please call 1-800-631-5244 from 8AM to 8PM ET, Monday through Friday (except holidays).